Antibody-drug conjugates (ADCs) have revolutionized oncology by linking the precise targeting of monoclonal antibodies with the ultrapotent activity of small-molecule payloads. Despite rapid advances in antibody and linker engineering, the field continues to r... ...

请注册登录后继续浏览